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Abstract
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family is known to play an important role in the pathogenesis of
osteoarthritis (OA), working on aggrecan degradation or altering the integrity of extracellular matrix (ECM). Thus, the main purpose of our study
was to define the role of vasoactive intestinal peptide (VIP) and corticotrophin-releasing factor (CRF), as immunoregulatory neuropeptides, on
ADAMTS production in synovial fibroblasts (SF) from OA patients and healthy donors (HD). OA- and HD-SF were stimulated with pro-inflamma-
tory mediators and treated with VIP or CRF. Both neuropeptides decreased ADAMTS-4, -5, -7 and -12 expressions, aggrecanase activity,
glycosaminoglycans (GAG), and cartilage oligomeric matrix protein (COMP) degradation after stimulation with fibronectin fragments (Fn-fs) in
OA-SF. After stimulation with interleukin-1b, VIP reduced ADAMTS-4 and -5, and both neuropeptides decreased ADAMTS-7 production and
COMP degradation. Moreover, VIP and CRF reduced Runx2 and b-catenin activation in OA-SF. Our data suggest that the role of VIP and CRF on
ADAMTS expression and cartilage degradation could be related to the OA pathology since scarce effects were produced in HD-SF. In addition,
their effects might be greater when a degradation loop has been established, given that they were higher after stimulation with Fn-fs. Our results
point to novel OA therapies based on the use of neuropeptides, since VIP and CRF are able to stop the first critical step, the loss of cartilage
aggrecan and the ECM destabilization during joint degradation.
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Introduction
Control of the structure and function of the extracellular matrix (ECM)
is a main role of ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family. They can be classified in four sub-
groups on the basis of their known substrates, for instance aggre-
cans, other proteoglycans, cartilage oligomeric matrix protein
(COMP) or procollagen. Consequently, they have essential roles in
tissue development and maintenance, and their dysregulation is asso-
ciated with a number of diseases such as arthritis, cancer, atheroscle-
rosis and central nervous system injury and disorders [1].
Osteoarthritis (OA) is a debilitating degenerative disease of articu-
lar joints, mainly characterized by articular cartilage degradation, sub-
chondral bone alterations and localized inflammation [2].
Osteoarthritis appears as a result of a progressive loss of aggrecan
from cartilage, leading to exposure of the collagen matrix and its
breakdown by metalloproteases [2–4]. Within the subgroup of aggre-
canases, ADAMTS-4 and -5 play important roles in OA, emerging as
therapeutic targets in arthritis [5]. They are constitutively expressed
in human chondrocytes and synovial fibroblasts (SF), and their
expression is induced by pro-inflammatory cytokines and products of
matrix degradation as fibronectin fragments (Fn-fs) [3, 6, 7]. Other
important molecule in the maintenance of cartilage is COMP that sta-
bilizes ECM via specific interactions with matrix components such as
collagen, aggrecan and fibronectin. Its degradation may also play a
key role in the pathogenesis of arthritis [3, 8]. ADAMTS-7 and -12
belongs to the COMP-cleaving enzymes subgroup. They are also pro-
duced by chondrocytes and SF and up-regulated by pro-inflammatory
mediators [3, Perez-Garcıa et al., unpublished data]. Moreover, their
overexpression is related to cartilage degenerative diseases and to
disease progression in a mouse model of arthritis [9, 10].
Neuropeptides present in the joints are important mediators able
to control several processes as inflammation, immunomodulation
and cartilage or bone maintenance. Vasoactive intestinal peptide
(VIP) and corticotropin-releasing factor (CRF) are two neuropeptides
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present in the joint released from nerve ending, lymphocytes or SF,
among other cells [11, 12]. Vasoactive intestinal peptide exerts anti-
inflammatory and immunomodulatory actions in several autoimmune
and inflammatory disorders [13, 14]. Treatment with VIP significantly
reduced incidence and severity of arthritis in a mouse experimental
model, completely abrogating joint swelling and destruction of carti-
lage and bone [15, 16]. In addition, VIP is able to reduce levels of
some enzymes involved in ECM degradation in FLS from OA patients
[17]. On the other hand, CRF can exert both pro- and anti-inflamma-
tory functions depending on the type of receptors, tissues and dis-
ease phases [18, 19]. Furthermore, some members of CRF family
have shown a protective role on cartilage and bone cellular mainte-
nance [20, 21].
All in all, ADAMTS play a key role in the cartilage destruction in
OA, and their modulation is essential for the maintenance of the
joints. Thus, the main purpose of our study was to define the role of
VIP and CRF on ADAMTS produced by SF, as important cells also
implicated in the maintenance of the cartilage ECM, in OA patients
and healthy donors (HD). To our knowledge, this is the first study
demonstrating that VIP and CRF can target the ADAMTS family
in vitro.
Patients and methods
Patients and SF cultures
Synovial tissue was obtained from 20 active OA patients (16 women
and 4 men) aged between 48 and 87 years, at the time of knee pros-
thetic replacement surgery. Patients had advanced disease and were
diagnosed of primary OA, excluding trauma, inflammatory disease, and
other structural causes of secondary OA. Control samples from HD
were obtained from four patients (2 women and 2 men) aged between
35 and 72 years, diagnosed with meniscopathy, excluding inflammatory
and rheumatic diseases, at the time of a knee arthroscopic evaluation.
The study was performed according to the recommendations of the
Declaration of Helsinki and was approved by the Clinical Research
Ethics Committee of the Hospital La Princesa (Madrid, Spain). All
biopsy samples were obtained after subjects gave their informed con-
sent.
Synovial fibroblasts cultures were established by explant growth of
synovial biopsies which were cultured in 10% heat-inactivated foetal
bovine serum (FBS)/DMEM (Lonza, Iberica S.A.U., Barcelona, Spain)
completed with 1% L-glutamine and 1% antibiotic–antimycotic (Invitro-
gen, Carlsbad, CA, USA), at 37°C and 5% CO2. After three passages,
residual contamination by macrophages was avoided and monocultures
of SF were obtained and used for experiments until passage 8.
Treatments of SF cultures
Healthy donors- and OA-SF were cultured in serum-free complete
DMEM in the absence (untreated) or in the presence of the following
agents: 10 ng/ml interleukin-1b (IL-1b; Immunotools GmbH, Friesoythe,
Germany) or 10 nM Fn-fs 45 kDa for 24 hrs. Fn-fs were commercially
predesigned from human plasma fibronectin (Sigma-Aldrich, St Louis,
MO, USA). These treatments were applied alone or in combination with
10 nM VIP (Polypeptide) or 10 nM CRF (Phoenix Pharmaceuticals, Inc,
Karlsruhe, Germany).
RNA extraction and RT-qPCR for ADAMTS gene
expression
Synovial fibroblasts were cultured in 100-mm petri dishes (3 9 105
cells/dish). Total RNA was obtained using TriReagent (Sigma-Aldrich).
2 lg RNA were reverse transcribed using a High Capacity cDNA Rev-
erse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Semi-
quantitative real-time PCR analysis was performed with a TaqMan
Gene Expression Master Mix with manufactured-predesigned primers
and probes for b-actin (NM001101.3), ADAMTS-4 (NM005099.4),
ADAMTS-5 (NM007038.3), ADAMTS-7 (NM014272.3) and ADAMTS-12
(NM030955.2) (Applied Biosystems). For relative quantification, we nor-
malized the target gene expression to the housekeeping gene (b-actin).
Results were presented as the relative expression with respect to the
untreated condition using the formula 2ΔΔCt, as previously described
[12].
Quantification of ADAMTS in culture supernatant
Synovial fibroblasts were cultured in six-well plates (6 9 104 cells/well).
The levels of ADAMTS were measured in the culture supernatants using
a commercial ELISA kits for ADAMTS-4 and -5 (Cloud-Clone Corp,
Houston, TX, USA), and ADAMTS-7 and -12 (MyBioSource, San Diego,
CA, USA).
Aggrecanase activity assay
Aggrecanase activity was measured in the SF culture supernatants from
100-mm petri dishes (3 9 105 cells/dish) using a Sensitive Aggre-
canase Activity ELISA kit (MD Bioproducts, Z€urich, Switzerland), accord-
ing to the manufacturer’s instructions. Briefly, this assay consists in
two modules. In the Aggrecanase Module, a modified interglobular
domain (aggrecan-IGD-s) is digested with aggrecanases, and its prote-
olytic cleavage releases an aggrecan peptide (ARGSVIL-peptide-s),
which is then quantified with antibodies in the ELISA Module.
Glycosaminoglycans and COMP assays in
cartilage-SF co-cultures
Release of glycosaminoglycans (GAGs) and COMP degradation prod-
ucts from cartilage tissue was measured in culture medium from wells
containing SF cultured over cartilage explants. Osteoarthritis human
cartilages were obtained from three patients undergoing total hip
arthroplasty in Hospital del Mar (Barcelona, Spain). Fixed diameter
(6 mm) and height (2 mm) sections were collected from cartilage
areas without macroscopically signs of OA. The samples were frozen
at 80°C and stored until testing. One explant per well was attached
to a 24 well plate. Healthy donors- or OA-SF were added drop-wise
on top of the cartilage surface (2 9 104 SF/explant). After 3 hrs of
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incubation at 37°C, wells were filled with 1 ml DMEM 10% FBS, with
the treatments described, and cultures were continued for 14 days.
Culture supernatants were collected to detect the release of GAGs and
COMP degradation products, using a BlyscanTM Sulfated Glycosamino-
glycan Assay (Biocolor Ltd, County Antrim, Ireland, UK), and a Quan-
tikine Human COMP Immunoassay (R&D Systems, Abingdon, OX,
UK), respectively. Cartilage explants were placed in OCT and frozen in
liquid nitrogen. Sections were prepared using a cryostat, placed on
slides and stained with Alcian blue and Callejas’s tricromic.
Runx2 Transcription factor activity assay
Synovial fibroblasts were cultured in 150-mm petri dishes (8 9 105
cells/dish). A Nuclear Extract Kit (Active Motif, Rixensart, Belgium) was
used for nuclear extract preparation, and the protein content was mea-
sured with a QuantiProTM BCA Assay Kit (Sigma-Aldrich). The nuclear
protein extracts (12 lg/well) were added to a 96-well plate and Runx2
activity was measured using a TransAMTM AML-3/Runx2 kit (Active
Motif). We studied the time course of Runx2 activation after incubation
with IL-1b or Fn-fs. Next, we performed the experiments at 60 min. or
30 min. respectively.
b-catenin assay
To detect b-catenin levels, a b-catenin (Total) and a (Phospho) Instan-
tOneTM ELISA kits were used (eBioscience, San Diego, CA, USA) with
SF cellular lysates. Briefly, SF cultured in 100-mm petri dishes
(3 9 105 cells/dish) were scraped into PBS, centrifuged and resus-
pended in the Cell Lysis Buffer Mix. Protein content was measured
using a QuantiProTM BCA Assay Kit (Sigma-Aldrich). The levels of b-
catenin in the cellular lysates were measured after 60 min. of treatment,
when the highest production of b-catenin was observed.
Statistical analysis
Samples were tested for normality by a Normality Test. Differences
between means of different groups (one-to-one comparisons) were
assessed using a Student’s two-tailed t-test with P < 0.05 considered
significant. Results are presented as the mean with a 95% confidence
interval (CI) (lower limit, upper limit). Data were analysed with Graph-
Pad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA).
Results
VIP and CRF decrease ADAMTS-4, -5, -7 and -12
expression and function after stimulation with
Fn-fs in SF from OA patients
Fibronectin fragments are ECM degradation products that act as
inflammatory mediators and contribute to joint destruction in OA
[22]. The presence of Fn-fs in OA-SF increased the expression of
ADAMTS [Perez-Garcıa et al., unpublished data]. Our results showed
that treatment with VIP and CRF reduced mRNA expression and pro-
tein secretion of ADAMTS-4, -7 and -12 induced by Fn-fs in OA-SF.
The mRNA expression and protein secretion of ADAMTS-5 were also
decreased by VIP, whereas CRF only decreased the mRNA expression
of these aggrecanases (Fig. 1A and B, right). By contrast, treatment
of HD-SF with these neuropeptides after stimulation with Fn-fs only
reduced the ADAMTS-4 protein production (Fig. 1A and B, left).
To further dissect the role of VIP and CRF on ADAMTS family,
we performed functional determinations of this metalloproteinases.
Degradation of aggrecan is catalysed by ADAMTS-4 and -5 [2–4].
Measurement of aggrecanase activity in culture supernatants
showed a significant reduction in Fn-fs-induced OA-SF after VIP
and CRF treatments (Fig. 2A, right). The aggrecanase activity acts
on aggrecan in the cartilage ECM releasing GAGs. We next studied
the capacity of SF to degrade the cartilage by measuring GAG
release in the supernatants of cartilage-SF co-cultures. When OA-SF
were treated with Fn-fs, VIP and CRF significantly decreased the
release of GAGs to the medium (Fig. 2B, right). None of the
neuropeptides induced changes in the aggrecanase activity and in
the GAGs release in HD-SF. On the other hand, ADAMTS-7 and -12
are associated with COMP, a non-collagenous component of the
cartilage ECM [3, 8]. Cartilage oligomeric matrix protein degrada-
tion products from cartilage tissue were measured in supernatants
from cartilage-SF co-cultures. Also, the presence of VIP and CRF in
OA-SF after induction with Fn-fs significantly decreased the release
of COMP fragments (Fig. 2C, right). No changes were observed in
the case of HD-SF (Fig. 2A–C, left).
VIP and CRF differently modulate ADAMTS-4, -5,
-7 and -12 expression and function after
stimulation with IL-1b in SF from OA patients
To determine whether the effects of VIP or CRF on Fn-fs-induced
ADAMTS could be extended to other pro-inflammatory mediators
present in the OA joints, we used the catabolic cytokine IL-1b to
induce ADAMTS expression in cultured SF. Previous studies have
demonstrated that IL-1b induces the expression of ADAMTS-4, -5, -7
and -12 in OA-SF [Perez-Garcıa et al., unpublished data, 23]. Here,
we showed that VIP decreased the synthesis of ADAMTS-4, -5 and -
7. However, treatment with CRF showed a different pattern. Although
CRF reduced both, mRNA expression and protein secretion of
ADAMTS-7, it did not show any effect on ADAMTS-4 and -5 (Fig. 3A
and B right). No changes were observed in ADAMTS-12 after VIP or
CRF treatments. The only effect observed in HD-SF induced by IL-1b
was a reduction in the ADAMTS-4 and -5 protein production after
VIP treatment (Fig. 3A and B left).
Furthermore, the effect of VIP and CRF on ADAMTS-4 and -5
expression after stimulation with IL-1b was not confirmed at func-
tional level. Aggrecanase activity and GAG release in the super-
natants of OA cartilage-SF co-cultures showed similar values in the
presence and absence of these neuropeptides (Fig. 4A and B, right).
Conversely, the presence of VIP and CRF in IL-1b-induced OA-SF
significantly decreased the release of COMP fragments, related to
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ADAMTS-7 and -12 actions (Fig. 4C, right). At functional level, no
changes were observed in IL-1b-induced HD-SF after VIP or CRF
treatment (Fig. 4 A–C, left).
VIP and CRF reduce activation of Runx2 and
b-catenin transcription factors in SF from OA
patients
To elucidate the mechanism involved in the modulation of the
ADAMTS family by VIP and CRF, we tested two transcription factors
that regulate gene expression of some ADAMTS, Runx2 and b-catenin
[24, 25]. Vasoactive intestinal peptide and CRF decreased the Runx2
activation induced by Fn-fs and IL-1b in OA-SF (Fig. 5A, right). The
other transcription factor studied, b-catenin, showed the same profile
(Fig. 5B, right). In this case, we measured the total b-catenin that
mainly represented the active form since the levels of phosphorylated
b-catenin were undetectable. No changes were observed in HD-SF
(Fig. 5A and B, left).
Discussion
At present, this is the first study demonstrating the role of two
endogenous neuropeptides present in the joint microenvironment,
VIP and CRF, on ADAMTS family in vitro. Destruction of the ECM
from the articular cartilage and subchondral bone in OA joints, is
thought to be mediated by excessive proteolytic activity as a result of
several events that take place in sequence [26]. The ADAMTS family
is known to play an important role in the pathogenesis of OA, working
on aggrecan degradation or altering the integrity of the ECM [8, 27–
Fig. 1mRNA and protein expression of ADAMTS in Fn-fs-induced OA-SF in the presence of VIP or CRF. (A) ADAMTS-4, -5, -7 and -12 mRNA
expression was measured after 24 hrs of treatment by RT-qPCR, normalized to b-actin and presented as the relative quantification with respect to
the untreated cells using the formula 2ΔΔCt (see Patients and methods). Values are presented as the mean  S.E.M. of HD (n = 4) (left) and OA
(n = 7) (right), performed in triplicate. (B) The presence of ADAMTS-4, -5, -7 and -12 in the supernatants was determined by ELISA after 24 hrs of
treatment. Values are presented as the percentage of untreated cells (mean  S.E.M.) of HD (n = 4) (left) and OA (n = 7) (right), performed in
duplicate. Dashed lines represent the untreated condition. Significant differences between treatments are indicated by a bar with the P-value above.
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29]. The inhibition of these degradation enzymes can slow down or
block disease progression. Thus, the characterization of mediators as
neuropeptides, which can modulate these enzymes, is of great impor-
tance for both physiopathological and therapeutic perspectives.
Vasoactive intestinal peptide is a mediator shared by the neuroen-
docrine-immune network, which is considered as a potential
candidate for treatment in inflammatory and autoimmune diseases
[13]. Recently, VIP has been considered as a clinical biomarker in
rheumatoid arthritis (RA) and OA, where low serum VIP levels were
associated with worse prognosis [30, 31]. In this way, VIP decreases
pro-inflammatory mediators and degradative proteases [11, 13, 17,
32]. Moreover, protective effects of VIP upon bone and cartilage
destruction have been described in experimentally induced arthritis
[15, 16]. Present results showed that VIP differentially affects
ADAMTS-4, -5, -7 and -12 in OA-SF depending on the inflammatory
mediator that induced their expression. When IL-1b was present, the
effect of VIP on ADAMTS-4 and -5 protein production was not con-
firmed at functional level. The aggrecanase activity in SF and the GAG
release in cartilage-SF co-cultures showed similar values in the
presence or absence of VIP, probably because of the fact that IL-1b
did not induce the aggrecanase activity in SF [Perez-Garcıa et al.,
unpublished data, 33, 34]. However, VIP decreased expression and
function of ADAMTS-4 and -5 when they were induced by Fn-fs, that
was reflected in the reduction in the aggrecanase activity as well as in
the decrease in GAGs liberated from the cartilage explants. In the case
of ADAMTS associated with COMP degradation, VIP diminished
ADAMTS-7 mRNA expression and protein production in OA-SF in the
presence of both inflammatory mediators. Interestingly, the expres-
sion of ADAMTS-7 is relatively late in OA development [8]. However,
ADAMTS-12 transcript and protein were only decreased after Fn-fs
stimulation. Since VIP significantly decreased COMP degradation
after both Fn-fs and IL-1b stimulation, altogether these data may sug-
gest that the effects observed are mainly mediated by ADAMTS-7.
Fibronectin fragments result from progressive cartilage degeneration
in injured joints and act as a continuous loop degrading cartilage
through up-regulation of cartilage degrading enzymes [Perez-Garcıa
et al., unpublished data, 35]. Our data suggest that the role of VIP
blocking ECM degradation through the modulation of ADAMTS
expression could be related to the OA pathology since scarce effects
were produced by VIP in HD-SF. In addition, its actions might be
Fig. 2 Aggrecanase activity and detection
of GAGs and COMP degradation products
in Fn-fs-induced OA-SF in the presence of
VIP or CRF. (A) Aggrecanase activity was
measured in culture supernatants by an
Aggrecanase Activity ELISA kit after
24 hrs of treatment. A mean of duplicate
determinations was obtained for each HD
(n = 4) (left) and OA (n = 5) (right). (B)
GAGs in the supernatants from cartilage-
SF co-cultures were detected after
14 days of treatment using a BlyscanTM
Sulfated Glycosaminoglycan Assay. A
mean of duplicate determinations was
obtained for each HD (n = 3) (left) and
OA (n = 3) (right). (C) COMP degradation
products in the supernatants from carti-
lage-SF co-cultures were detected after
14 days of treatment using a Quantikine
Human COMP Immunoassay. A mean of
triplicate determinations was obtained for
each HD (n = 3) (left) and OA (n = 3)
(right). Dashed lines represent the
untreated condition. Values are presented
as the percentage of untreated cells
(mean  S.E.M.). Significant differences
between treatments are indicated by a bar
with the P-value above.
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higher when a degradation loop has been established given that the
greater effects were observed after induction by Fn-fs, present only in
the late stages of OA.
Corticotrophin-releasing factor has also an important role in
the homoeostasis, both systematically and locally. An increasing
body of data point to an anti-inflammatory action of CRF in vitro
[18, 36, 37]. Besides, low CRF levels are clearly associated with
disease severity in a human autoimmune disease [38]. Another
member of its family, urocortin, is implicated in osteoclast differ-
entiation and is also related to the maintenance of the cartilage
and bone in OA [20, 21]. We observed that CRF had similar
effects to VIP on ADAMTS-7 and -12 expression and production
after treatment with IL-1b and Fn-fs, and on ADAMTS-4 and -5
expressions only after Fn-fs stimulation, with no effect after
induction with IL-1b. At functional level, the effects observed with
both neuropeptides were similar, decreasing the action of
ADAMTS-7 and -12 after both stimuli, and ADAMTS-4 and-5 func-
tions only after Fn-fs stimulation. These results may point out
that CRF could block ECM degradation in OA modulating ADAMTS
expression, in a similar way to VIP in late stages of the disease
when a degradation loop has already been established. Moreover,
a crosstalk between VIP and CRF in RA and OA has also been
described [12]. In addition, it is also important to consider that
some pathophysiological conditions that take place during the dis-
ease can affect the release of this neuropeptides, modifying their
levels [30, 31].
Fig. 3mRNA and protein expression of ADAMTS in IL-1b-induced OA-SF in the presence of VIP or CRF. (A) ADAMTS-4, -5, -7 and -12 mRNA
expression after 24 hrs of treatment was measured by RT-qPCR, normalized to b-actin mRNA expression and presented as the relative quantifica-
tion with respect to the untreated cells using the formula 2ΔΔCt (see Patients and methods). Values are presented as the mean  S.E.M. of HD
(n = 4) (left) and OA (n = 7) (right), performed in triplicate. (B) The presence of ADAMTS-4, -5, -7 and -12 in the supernatants was determined by
ELISA after 24 hrs of treatment. Values are presented as the percentage of untreated cells (mean  S.E.M.) of HD (n = 4) (left) and OA (n = 7)
(right), performed in duplicate. Dashed lines represent the untreated condition. Significant differences between treatments are indicated by a bar with
the P-value above.
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Runx 2 is an important transcription factor involved in both histo-
genesis and maintenance of the skeletal tissue, as well as in chondro-
cytes maturation and hypertrophy in OA [39, 40]. On the other hand,
b-catenin is implicated in chondrocytes differentiation and skeletal
maintenance, related to osteoblast differentiation and the blockade of
osteoclastogenesis, which plays an important role in the pathology of
OA [41–43]. Several studies have demonstrated that Runx2 and b-
catenin are associated to ADAMTS-4 and -5 [24, 25, 44], neverthe-
less, there are no studies related to the transcription factors involved
in ADAMTS-7 and -12 gene expressions. Here, we showed that VIP
and CRF reduced activation of Runx2 and b-catenin transcription fac-
tors in OA-SF after induction by IL-1b and Fn-fs in OA-SF. As part of
the anti-inflammatory action of both neuropeptides [13, 14, 18, 19],
the effects of VIP and CRF on ADAMTS could be mediated by the
blockade of both transcription factors. Vasoactive intestinal peptide
and CRF have demonstrated a protective role in cartilage and bone
maintenance [15, 16, 20, 21, 45]. This effect will depend on the cell
type, the signalling pathways involved, and the interaction between
the different cells present in the joint. Previous data reported the
same effect of VIP on b-catenin in renal cancer cells [46]. In relation
to CRF, it has only been described that Wnt/b-catenin signalling path-
way is increased by CRF in a mouse pituitary corticotroph cancer cells
[47]. Discrepancy with our results could be because of the different
samples under study. Moreover, this is the first report demonstrating
the modulation of Runx2 by VIP and CRF in vitro. Different studies
have described that VIP activates PKA phosphorylating CREB inhibit-
ing c-Jun an AP-1 in RA and OA-SF [15, 48, 49]. PKA/CREB signalling
is also activated by CRF [50]. As Runx2 is activated by c-Jun [51],
this signalling pathway could be implicated in the decrease in Runx2
observed after treatment with VIP and CRF. Moreover, it could impact
in the effect observed on b-catenin, as both signalling pathways are
connected [52]. On the other hand, it has been shown that the tran-
scription factor NFjB plays an important role regulating different
proinflammatory and destructive mediators in OA, including several
matrix metalloproteases and ADAMTS [53, 54]. In this sense, it
has been reported that VIP decreases NFjB in synovial cells form
CIA-treated mice [15, 48]. Then, the blockade of this signalling path-
way could also be implicated in the decrease in the ADAMTS expres-
sion observed after treatment with VIP.
Regarding the effect of other neuropeptides on ADAMTS and
consequently on ECM maintenance, data are scarce, even more in
OA pathology. Only one study described that calcitonin decreases
ADAMTS-4 expression in a mouse model of OA [55], having a
chondroprotective effect in a rabbit model of early OA [56]. We have
demonstrated that VIP and CRF are able to decrease ADAMTS
expression and function in OA-SF. Indeed, VIP reduces uPA (uroki-
nase-type plasminogen activator) in OA-SF, a proteolytic enzyme
upstream of the ADAMTS [17]. The uPA-ADAMTS axis is the main
Fig. 4 Aggrecanase activity and detection
of GAGs and COMP degradation products
in OA-SF after stimulation with IL-1b in
the presence of VIP or CRF. (A) Aggre-
canase activity was measured in culture
supernatants by Aggrecanase Activity
ELISA kit after 24 hrs of treatment. A
mean of duplicate determinations was
obtained for each HD (n = 4) (left) and
OA (n = 5) (right). (B) GAGs in the super-
natants from cartilage-SF co-cultures were
detected after 14 days of treatment using
a BlyscanTM Sulfated Glycosaminoglycan
Assay. A mean of duplicate determinations
was obtained for each HD (n = 3) (left)
and OA (n = 3) (right). (C) COMP degra-
dation products in the supernatants from
cartilage-SF co-cultures were detected
after 14 days of treatment using a Quan-
tikine Human COMP Immunoassay. A
mean of triplicate determinations was
obtained for each HD (n = 3) (left) and
OA (n = 3) (right). Dashed lines represent
the untreated condition. Values are pre-
sented as the percentage of untreated
cells (mean  S.E.M.). Significant differ-
ences between treatments are indicated by
a bar with the P-value above.
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responsible for aggrecan cleavage and cartilage loss in OA. Matrix
metalloproteinases (MMPs) participate downstream in this process
and continue with the degradation of collagen [26]. In this sense,
VIP decreases MMP-9 and -13 in OA-SF after IL-1b and Fn-fs
stimulation [17].
Although more studies are needed to elucidate the mechanism of
action of VIP and CRF, our results point to novel targets to relieve the
destruction of cartilage ECM in OA joints. Considering that VIP and
CRF are able to modulate the first critical step, the loss of aggrecan in
the destabilization of cartilage ECM, we corroborate the role of
neuropeptides as potential therapeutic targets. Emerging therapies
that directly or indirectly inhibit ADAMTS often lead to favourable out-
come in OA patients.
Acknowledgements
We are grateful to all patients and the collaborating clinicians for their
participation in this study. This study was supported by a grant from
Red de Investigacion en Inflamacion y Enfermedades Reumaticas (RIER)
(RD12/0009/0002 to MC), a grant from Instituto de Salud Carlos III,
Spain, co-financed by FEDER, European Union (PI12/00758 to SPG), and
a grant from Comunidad de Madrid/FEDER (RAPHYME program, S2010/
BMD2350).
Conflicts of interest
A patent application (P201230827) for the use of VIP as a prognostic
marker in autoimmune diseases has been deposited by the Biomedi-
cal Research Foundation of La Princesa University Hospital and Com-
plutense University of Madrid at the Oficina Espa~nola de Patentes y
Marcas. The full name of the patent application is: VIP use as a prog-
nostic marker of autoimmune diseases.
Author contribution
SPG performed the research; RPG and YJ designed the research
study; SPG and MC analysed the data; IGA collected the samples;
RPG, YJ, SPG and IGC wrote the paper.
References
1. Kelwick R, Desanlis I, Wheeler GN, et al.
The ADAMTS (A Disintegrin and Metallopro-
teinase with Thrombospondin motifs) family.
Genome Biol. 2015; 16: 113.
2. Loeser RF, Goldring SR, Scanzello CR,
et al. Osteoarthritis: a disease of the joint as
an organ. Arthritis Rheum. 2012; 64: 1697–
707.
3. Lin EA, Liu CJ. The role of ADAMTSs in
arthritis. Protein Cell. 2010; 1: 33–47.
4. Troeberg L, Nagase H. Proteases involved
in cartilage matrix degradation in
Fig. 5 Runx2 and b-catenin activation in
OA-SF after Fn-fs or IL-1b in the presence
of VIP or CRF. (A) Runx2 activation was
measured after treatment with IL-1b for
60 min. or Fn-fs for 30 min. in the pres-
ence or absence of VIP or CRF, in OA-SF
nuclear extracts by TransAMTM. A mean of
duplicate determinations was obtained for
each HD (n = 4) (left) and OA (n = 4)
(right). (B) b-catenin levels were detected
after treatment with IL-1b or Fn-fs for
60 min. in the presence or absence of VIP
or CRF, in OA-SF cellular lysates by
ELISA. A mean of duplicate determinations
was obtained for each HD (n = 4) (left)
and OA (n = 5) (right). Dashed lines rep-
resent the untreated condition. Values are
presented as the percentage of untreated
cells (mean  S.E.M.). Significant differ-
ences between treatments are indicated by
a bar with the P-value above.
8 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
osteoarthritis. Biochim Biophys Acta. 2012;
1824: 133–45.
5. Dancevic CM, McCulloch DR.
Current and emerging therapeutic strate-
gies for preventing inflammation and
aggrecanase-mediated cartilage destruction
in arthritis. Arthritis Res Ther. 2014; 16:
429.
6. Ismail HM, Yamamoto K, Vincent TL, et al.
Interleukin-1 acts via the JNK-2 signaling
pathway to induce aggrecan degradation by
human chondrocytes. Arthritis Rheumatol.
2015; 67: 1826–36.
7. Stanton H, Ung L, Fosang AJ. The 45 kDa
collagen-binding fragment of fibronectin
induces matrix metalloproteinase-13 synthe-
sis by chondrocytes and aggrecan degrada-
tion by aggrecanases. Biochem J. 2002;
364: 181–90.
8. Lai Y, Bai X, Zhao Y, et al. ADAMTS-7
forms a positive feedback loop with TNF-
alpha in the pathogenesis of osteoarthritis.
Ann Rheum Dis. 2014; 73: 1575–84.
9. Zhang Y, Wei F, Liu CJ. Overexpression of
ADAMTS-7 leads to accelerated initiation
and progression of collagen-induced arthritis
in mice. Mol Cell Biochem. 2015; 404: 171–
9.
10. Zhang Q, Huang M, Wang X, et al. Negative
effects of ADAMTS-7 and ADAMTS-12 on
endplate cartilage differentiation. J Orthop
Res. 2012; 30: 1238–43.
11. Juarranz Y, Gutierrez-Canas I, Santiago B,
et al. Differential expression of vasoactive
intestinal peptide and its functional receptors
in human osteoarthritic and rheumatoid syn-
ovial fibroblasts. Arthritis Rheum. 2008; 58:
1086–95.
12. Perez-Garcia S, Juarranz Y, Carrion M,
et al. Mapping the CRF-urocortins system
in human osteoarthritic and rheumatoid
synovial fibroblasts: effect of vasoactive
intestinal peptide. J Cell Physiol. 2011; 226:
3261–9.
13. Gomariz RP, Juarranz Y, Abad C, et al. VIP-
PACAP system in immunity: new insights for
multitarget therapy. Ann N Y Acad Sci. 2006;
1070: 51–74.
14. Gomariz RP, Gutierrez-Canas I, Arranz A,
et al. Peptides targeting Toll-like receptor
signalling pathways for novel immune thera-
peutics. Curr Pharm Des. 2010; 16: 1063–
80.
15. Juarranz Y, Abad C, Martinez C, et al. Pro-
tective effect of vasoactive intestinal peptide
on bone destruction in the collagen-induced
arthritis model of rheumatoid arthritis.
Arthritis Res Ther. 2005; 7: R1034–45.
16. Delgado M, Abad C, Martinez C, et al.
Vasoactive intestinal peptide prevents exper-
imental arthritis by downregulating both
autoimmune and inflammatory components
of the disease. Nat Med. 2001; 7: 563–8.
17. Perez-Garcia S, Carrion M, Jimeno R, et al.
Urokinase plasminogen activator system in
synovial fibroblasts from osteoarthritis
patients: modulation by inflammatory medi-
ators and neuropeptides. J Mol Neurosci.
2014; 52: 18–27.
18. Tsatsanis C, Androulidaki A, Dermitzaki E,
et al. Corticotropin releasing factor receptor
1 (CRF1) and CRF2 agonists exert an anti-
inflammatory effect during the early phase
of inflammation suppressing LPS-induced
TNF-alpha release from macrophages via
induction of COX-2 and PGE2. J Cell Physiol.
2007; 210: 774–83.
19. Tsatsanis C, Dermitzaki E, Venihaki M,
et al. The corticotropin-releasing factor
(CRF) family of peptides as local modulators
of adrenal function. Cell Mol Life Sci. 2007;
64: 1638–55.
20. Combs CE, Fuller K, Kumar H, et al. Uro-
cortin is a novel regulator of osteoclast dif-
ferentiation and function through inhibition
of a canonical transient receptor potential 1-
like cation channel. J Endocrinol. 2012; 212:
187–97.
21. Intekhab-Alam NY, White OB, Getting SJ,
et al. Urocortin protects chondrocytes from
NO-induced apoptosis: a future therapy for
osteoarthritis? Cell Death Dis. 2013; 4:
e717.
22. Yasuda T. Activation of Akt leading to
NF-kappaB up-regulation in chondrocytes
stimulated with fibronectin fragment.
Biomed Res. 2011; 32: 209–15.
23. Imada K, Oka H, Kawasaki D, et al. Anti-
arthritic action mechanisms of natural
chondroitin sulfate in human articular chon-
drocytes and synovial fibroblasts. Biol
Pharm Bull. 2010; 33: 410–4.
24. Thirunavukkarasu K, Pei Y, Moore TL, et al.
Regulation of the human ADAMTS-4 pro-
moter by transcription factors and cytokines.
Biochem Biophys Res Commun. 2006; 345:
197–204.
25. Thirunavukkarasu K, Pei Y, Wei T. Charac-
terization of the human ADAMTS-5 (aggre-
canase-2) gene promoter. Mol Biol Rep.
2007; 34: 225–31.
26. Rengel Y, Ospelt C, Gay S. Proteinases in the
joint: clinical relevance of proteinases in joint
destruction. Arthritis Res Ther. 2007; 9: 221.
27. Huang K, Wu LD. Aggrecanase and aggre-
can degradation in osteoarthritis: a review. J
Int Med Res. 2008; 36: 1149–60.
28. Durigova M, Troeberg L, Nagase H, et al.
Involvement of ADAMTS5 and hyaluronidase
in aggrecan degradation and release from
OSM-stimulated cartilage. Eur Cell Mater.
2011; 21: 31–45.
29. Zhang E, Yan X, Zhang M, et al. Aggre-
canases in the human synovial fluid at differ-
ent stages of osteoarthritis. Clin Rheumatol.
2013; 32: 797–803.
30. Jiang W, Gao SG, Chen XG, et al. Expres-
sion of synovial fluid and articular cartilage
VIP in human osteoarthritic knee: a new indi-
cator of disease severity? Clin Biochem.
2012; 45: 1607–12.
31. Martinez C, Ortiz AM, Juarranz Y, et al.
Serum levels of vasoactive intestinal Peptide
as a prognostic marker in early arthritis.
PLoS ONE. 2014; 9: e85248.
32. Carrion M, Juarranz Y, Seoane IV, et al.
VIP modulates IL-22R1 expression and
prevents the contribution of rheumatoid
synovial fibroblasts to IL-22-mediated joint
destruction. J Mol Neurosci. 2014; 52:
10–7.
33. Vankemmelbeke MN, Holen I, Wilson AG,
et al. Expression and activity of ADAMTS-5
in synovium. Eur J Biochem. 2001; 268:
1259–68.
34. Yamanishi Y, Boyle DL, Clark M, et al.
Expression and regulation of aggrecanase in
arthritis: the role of TGF-beta. J Immunol.
2002; 168: 1405–12.
35. Ding L, Guo D, Homandberg GA, et al. A
single blunt impact on cartilage promotes
fibronectin fragmentation and upregulates
cartilage degrading stromelysin-1/matrix
metalloproteinase-3 in a bovine ex vivo
model. J Orthop Res. 2014; 32: 811–8.
36. Dermitzaki E, Liapakis G, Androulidaki A,
et al. Corticotrophin-Releasing Factor (CRF)
and the urocortins are potent regulators of
the inflammatory phenotype of human and
mouse white adipocytes and the differentia-
tion of mouse 3T3L1 pre-adipocytes. PLoS
ONE. 2014; 9: e97060.
37. Ullewar MP, Umathe SN. A possible role of
endogenous central corticotrophin releasing
factor in lipopolysaccharide induced thymic
involution and cell apoptosis: effect of
peripheral injection of corticotrophin releas-
ing factor. J Neuroimmunol. 2015; 280: 58–
65.
38. Melief J, de Wit SJ, van Eden CG, et al. HPA
axis activity in multiple sclerosis correlates
with disease severity, lesion type and gene
expression in normal-appearing white matter.
Acta Neuropathol. 2013; 126: 237–49.
39. Long F, Ornitz DM. Development of the
endochondral skeleton. Cold Spring Harb
Perspect Biol. 2013; 5: a008334.
40. van der Kraan PM, van den Berg WB. Chon-
drocyte hypertrophy and osteoarthritis: role
in initiation and progression of cartilage
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
9
J. Cell. Mol. Med. Vol XX, No X, 2016
degeneration? Osteoarthritis Cartilage. 2012;
20: 223–32.
41. Luyten FP, Tylzanowski P, Lories RJ. Wnt
signaling and osteoarthritis. Bone. 2009; 44:
522–7.
42. Corr M. Wnt-beta-catenin signaling in the
pathogenesis of osteoarthritis. Nat Clin Pract
Rheumatol. 2008; 4: 550–6.
43. Niedzwiedzki T, Filipowska J. Bone remod-
eling in the context of cellular and systemic
regulation: the role of osteocytes and the
nervous system. J Mol Endocrinol. 2015;
55: R23–36.
44. Yuasa T, Otani T, Koike T, et al. Wnt/b-
catenin signaling stimulates matrix catabolic
genes and activity in articular chondrocytes:
its possible role in joint degeneration. Lab
Invest. 2008; 88: 264–74.
45. Juhasz T, Helgadottir SL, Tamas A, et al.
PACAP and VIP signaling in chondrogenesis
and osteogenesis. Peptides. 2015; 66: 51–7.
46. Vacas E, Arenas MI, Munoz-Moreno L,
et al. Antitumoral effects of vasoactive
intestinal peptide in human renal cell
carcinoma xenografts in athymic nude mice.
Cancer Lett. 2013; 336: 196–203.
47. Khattak MN, Buchfelder M, Kleindienst A,
et al. CRH and SRIF have opposite effects
on the Wnt/beta-catenin signalling pathway
through PKA/GSK-3beta in corticotroph
pituitary cells. Cancer Invest. 2010; 28: 797–
805.
48. Delgado M, Munoz-Elias EJ, Kan Y, et al.
Vasoactive intestinal peptide and pituitary
adenylate cyclase-activating polypeptide
inhibit tumor necrosis factor alpha tran-
scriptional activation by regulating nuclear
factor-kB and cAMP response element-
binding protein/c-Jun. J Biol Chem. 1998;
273: 31427–36.
49. Carrion M, Juarranz Y, Perez-Garcia S,
et al. RNA sensors in human osteoarthritis
and rheumatoid arthritis synovial fibroblasts:
immune regulation by vasoactive intestinal
peptide. Arthritis Rheum. 2011; 63: 1626–
36.
50. Hauger RL, Risbrough V, Oakley RH, et al.
Role of CRF receptor signaling in stress
vulnerability, anxiety, and depression. Ann N
Y Acad Sci. 2009; 1179: 120–43.
51. Vimalraj S, Arumugam B, Miranda PJ,
et al. Runx2: structure, function, and phos-
phorylation in osteoblast differentiation. Int
J Biol Macromol. 2015; 78: 202–8.
52. Gaur T, Lengner CJ, Hovhannisyan H, et al.
Canonical WNT signaling promotes osteoge-
nesis by directly stimulating Runx2 gene
expression. J Biol Chem. 2005; 280: 33132–
40.
53. Bondeson J, Wainwright S, Hughes C, et al.
The regulation of the ADAMTS4 and ADAMTS5
aggrecanases in osteoarthritis: a review. Clin
Exp Rheumatol. 2008; 26: 139–45.
54. Wang Z, Hutton WC, Yoon ST. Bone mor-
phogenetic protein-7 antagonizes tumor
necrosis factor-alpha-induced activation of
nuclear factor kappaB and up-regulation of
the ADAMTS, leading to decreased degrada-
tion of disc matrix macromolecules
aggrecan and collagen II. Spine J. 2014; 14:
505–12.
55. Cheng T, Zhang L, Fu X, et al. The
potential protective effects of calcitonin
involved in coordinating chondrocyte
response, extracellular matrix, and sub-
chondral trabecular bone in experimental
osteoarthritis. Connect Tissue Res. 2013;
54: 139–46.
56. Mero A, Campisi M, Favero M, et al. A hya-
luronic acid-salmon calcitonin conjugate for
the local treatment of osteoarthritis: chon-
dro-protective effect in a rabbit model of
early OA. J Control Release. 2014; 187:
30–8.
10 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
View publication stats
